Predict your next investment

Other
yellowstoneholding.ch

See what CB Insights has to offer

Investments

2

About Yellowstone Holding

Yellowstone Holding is a long-term strategic investor seeking Swiss startups with growth plans in Asia.

Yellowstone Holding Headquarter Location

Route de Suisse 160-162 Versoix

Geneva, 1290,

Switzerland

+41 (0) 22 775 0410

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Yellowstone Holding News

Calciscon raises CHF 2.5M Series A to conquer the European market

Apr 15, 2021

15.04.2021 16:45 Calciscon AG, the provider of CE-marked T50 blood test, announced the closing of its Series A financing led by Yellowstone Holding. The financing proceeds enable the company to accelerate the introduction of the T50 test in routine clinical use in Europe and prepare for US launch. Calciscon was founded in 2013 as a result of breakthrough research in renal medicine by Andreas Pasch who investigated why the blood vessels of kidney patients calcify rapidly. His work led to the development of the T50 Calcification Propensity test (T50 test), the first functional test to assess the speed of calcification in the body. T50 identifies patients with high cardiovascular risk and opens the possibility to guide therapies to slow down disease progression. This information helps doctors better guide therapies of kidney disease patients. Chronic kidney disease (CKD) affects around 10% of the world population. Unfortunately, the current standard of care leaves most CKD patients suffering and dying from cardiovascular (CV) disease. Since the introduction of the T50 test, studies with nearly 20,000 patients have been published in peer-reviewed medical journals, demonstrating the clinical value of T50 in predicting CV complications. The CE-Marked T50 blood test received is currently available to patients in Switzerland through Labor Risch, Synlab and the central laboratory of University Hospital Bern (Inselspital). The company plans to extend the coverage to additional European countries while preparing for a US launch. With the closing of its CHF 2.5 million series A round, the startup is now braced for further growth. The funds will allow the company to commercialise the T50 test to drive more efficient therapies for renal patients. The round was raised from a group of investors led by Switzerland-based Yellowstone Holding, whose parent company already owns other strategic assets in kidney disease care. The startup has so far raised a total of CHF 5M cumulated equity investment. “The Series A funds are instrumental for bringing T50 to nephrologists to enable them to improve patient care”, said Vincent Linder, CEO. “The T50 immediately answers large unmet medical needs in improving the treatment of kidney disease patients”, explains Chan-Yuan Lu from Yellowstone. “Our consulting kidney care experts are very interested in starting to use the T50 to address CV complications”. Multiple intervention studies show that existing therapies can be adjusted to slow down calcification propensity significantly. “The T50 creates an unprecedented opportunity to reduce the extensive harm and healthcare costs associated with CV complications”, continues Andreas Pasch, nephrologist, inventor of the T50 test and founder of Calciscon. (Press release/RAN)

Yellowstone Holding Investments

2 Investments

Yellowstone Holding has made 2 investments. Their latest investment was in Calciscon as part of their Series A on April 4, 2021.

CBI Logo

Yellowstone Holding Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/14/2021

Series A

Calciscon

$2.71M

Yes

1

6/27/2018

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/14/2021

6/27/2018

Round

Series A

Series A

Company

Calciscon

Subscribe to see more

Amount

$2.71M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

1

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.